SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells
- PMID: 29858584
- PMCID: PMC6274620
- DOI: 10.1038/s41375-018-0152-7
SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells
Abstract
Recurrent mutations in the splicing factor SRSF2 are associated with poor clinical outcomes in myelodysplastic syndromes (MDS). Their high frequency suggests these mutations drive oncogenesis, yet the molecular explanation for this process is unclear. SRSF2 mutations could directly affect pre-mRNA splicing of a vital gene product; alternatively, a whole network of gene products could be affected. Here we determine how SRSF2 mutations globally affect RNA binding and splicing in vivo using HITS-CLIP. Remarkably, the majority of differential binding events do not translate into alternative splicing of exons with SRSF2P95H binding sites. Alternative splice alterations appear to be dominated by indirect effects. Importantly, SRSF2P95H targets are enriched in RNA processing and splicing genes, including several members of the hnRNP and SR families of proteins, suggesting a "splicing-cascade" phenotype wherein mutation of a single splicing factor leads to widespread modifications in multiple RNA processing and splicing proteins. We show that splice alteration of HNRNPA2B1, a splicing factor differentially bound and spliced by SRSF2P95H, impairs hematopoietic differentiation in vivo. Our data suggests a model whereby the recurrent mutations in splicing factors set off a cascade of gene regulatory events that together affect hematopoiesis and drive cancer.
Conflict of interest statement
The authors declare no conflict of interest
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6274620/bin/nihms962049f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6274620/bin/nihms962049f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6274620/bin/nihms962049f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6274620/bin/nihms962049f4.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6274620/bin/nihms962049f5.gif)
Similar articles
-
Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice.Blood. 2018 Feb 8;131(6):621-635. doi: 10.1182/blood-2017-01-762393. Epub 2017 Nov 16. Blood. 2018. PMID: 29146882 Free PMC article.
-
SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing.Mol Cell Biol. 2015 Sep 1;35(17):3071-82. doi: 10.1128/MCB.00202-15. Epub 2015 Jun 29. Mol Cell Biol. 2015. PMID: 26124281 Free PMC article.
-
Recurrent SRSF2 mutations in MDS affect both splicing and NMD.Genes Dev. 2020 Mar 1;34(5-6):413-427. doi: 10.1101/gad.332270.119. Epub 2020 Jan 30. Genes Dev. 2020. PMID: 32001512 Free PMC article.
-
Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.Adv Biol Regul. 2017 Jan;63:59-70. doi: 10.1016/j.jbior.2016.08.001. Epub 2016 Aug 21. Adv Biol Regul. 2017. PMID: 27639445 Review.
-
Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis.Hematology. 2018 Dec;23(10):778-784. doi: 10.1080/10245332.2018.1471794. Epub 2018 May 14. Hematology. 2018. PMID: 29757120 Review.
Cited by
-
Biological relevance of alternative splicing in hematologic malignancies.Mol Med. 2024 May 17;30(1):62. doi: 10.1186/s10020-024-00839-2. Mol Med. 2024. PMID: 38760666 Free PMC article. Review.
-
RBM10 C761Y mutation induced oncogenic ASPM isoforms and regulated β-catenin signaling in cholangiocarcinoma.J Exp Clin Cancer Res. 2024 Apr 4;43(1):104. doi: 10.1186/s13046-024-03030-x. J Exp Clin Cancer Res. 2024. PMID: 38576051 Free PMC article.
-
SRSF2 plays an unexpected role as reader of m5C on mRNA, linking epitranscriptomics to cancer.Mol Cell. 2023 Dec 7;83(23):4239-4254.e10. doi: 10.1016/j.molcel.2023.11.003. Mol Cell. 2023. PMID: 38065062
-
Incorporating mutational heterogeneity to identify genes that are enriched for synonymous mutations in cancer.BMC Bioinformatics. 2023 Dec 7;24(1):462. doi: 10.1186/s12859-023-05521-8. BMC Bioinformatics. 2023. PMID: 38062391 Free PMC article.
-
Secondary-Type Mutations in Acute Myeloid Leukemia: Updates from ELN 2022.Cancers (Basel). 2023 Jun 22;15(13):3292. doi: 10.3390/cancers15133292. Cancers (Basel). 2023. PMID: 37444402 Free PMC article. Review.
References
-
- Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous